The Simplify Volatility Premium ETF (SVOL) has delivered a 3% gain year-to-date and a 14% gain over 12 months, with a high forward yield of about 20.7% from monthly distributions. SVOL profits by selling short-term VIX futures and using tail hedges, thriving in calm volatility conditions. Investors should monitor the VIX futures curve, as an inversion (backwardation) can reduce returns and affect distributions. The fund's monthly payout has slightly decreased from $0.30 to $0.28, signaling a thinner volatility premium. Future distribution announcements and the shape of the VIX futures curve will be key indicators for SVOL's performance going forward.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Bitcoin Cash (BCH) fell about 4.5% on November 8, extending its weekly losses beyond 13%, while Bitcoin remained stable near $75,800. BCH's price dropped below key support levels around $250 and tested $244, signaling weaker demand compared to Bitcoi...
